| ABSTRACT Objective:To provide reference for the individualized treatment of opioid drugs by investigating the effects of OPRM1 gene A118G polymorphism on opioids dosage in patients with cancer pain.Methods: The Cochrane Library, PubMed, Embase, Medline, CNKI, WanFang Data and VIP database were searched to collect studies about A118G polymorphism of OPRM1 gene and dose of opioids in patients with cancer pain, the retrieval time was from the establishment to December 31, 2017. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, Meta analysis was performed by RevMan 5.3 software. Results:A total of five articles with 459 patients were included. Genetic testing showed that OPRM1 gene A118G polymorphism divided into mutant homozygote GG, wild type heterozygous AG and wild homozygous AA. The results of single group rate meta analysis showed, the does of opioid analgesics for patients with mutant homozygote GG was higher than the wild type heterozygous AG [SMD=-39.74, 95%CI (-59.20, -20.28), P＜0.001], the does of opioid analgesics for patients with mutant homozygote GG was higher than wild homozygous AA [SMD=-48.77, 95%CI(-68.01, -29.53), P＜0.000 1]. 〖WTHZ〗Conclusion:〖WTBZ〗Based on current research showed that OPRM1 gene A118G single nucleotide polymorphisms were associated with patients carrying the G allele increased the requirement of opioids. |
